1: Cheer SM, McClellan K. Manidipine: a review of its use in hypertension. Drugs. 2001;61(12):1777-99. doi: 10.2165/00003495-200161120-00010. 7:212509. doi: 10.7573/dic.212509. 3: McKeage K, Scott LJ. Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64(17):1923-40. doi: 10.2165/00003495-200464170-00011. 66(7):961-9. doi: 10.2165/00003495-200666070-00014. 65 Suppl
合成参考文献
参考文献:10.1038/s41371-018-0066-x 摘要:Wang G, Chen Y, Li L, Tang W, Wright JM. First-line renin–angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus. Journal of Human Hypertension. 2018 May 01;32(7):494–506. doi: 10.1038/s41371-018-0066-x. 参考文献:10.2165/00003088-199732010-00004 摘要:Schall R, Müller FR, Müller FO, Luus HG. Bioequivalence of controlled-release calcium antagonists. Clin Pharmacokinet. 1997 Jan;32(1):75–89. doi: 10.2165/00003088-199732010-00004. 参考文献:10.1007/bf03346639 摘要:Zaletel J, Pongrac Barlovic D, Prezelj J. Adiponectin-leptin ratio: A useful estimate of insulin resistance in patients with Type 2 diabetes. Journal of Endocrinological Investigation. 2010 Feb 05;33(8):514–8. doi: 10.1007/bf03346639.